BridgeBio shares preliminary data from CANaspire Phase 1/2 trial of BBP-812

TIPRANKS10-24

BridgeBio (BBIO) Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of BBP-812, an...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477682302?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-24 19:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477682302","market":"us","top_or_hot":-1,"title":"BridgeBio shares preliminary data from CANaspire Phase 1/2 trial of BBP-812","media":"TIPRANKS","content":"<div>\n<p>BridgeBio (BBIO) Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of BBP-812, an...</p>\n\n<a href=\"https://www.tipranks.com/news/the-fly/bridgebio-shares-preliminary-data-from-canaspire-phase-1-2-trial-of-bbp-812?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio shares preliminary data from CANaspire Phase 1/2 trial of BBP-812</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio shares preliminary data from CANaspire Phase 1/2 trial of BBP-812\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-24 19:45 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/the-fly/bridgebio-shares-preliminary-data-from-canaspire-phase-1-2-trial-of-bbp-812?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BridgeBio (BBIO) Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of BBP-812, an...</p>\n\n<a href=\"https://www.tipranks.com/news/the-fly/bridgebio-shares-preliminary-data-from-canaspire-phase-1-2-trial-of-bbp-812?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBP","symbol_name":"Virtus LifeSci Biotech Products ETF","start_time":0,"source_url":"https://www.tipranks.com/news/the-fly/bridgebio-shares-preliminary-data-from-canaspire-phase-1-2-trial-of-bbp-812?utm_source=itigerup.com&utm_medium=referral","article_id":"2477682302","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bridgebio-shares-preliminary-data-from-canaspire-phase-1-2-trial-of-bbp-812?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2477682302","pubTimestamp":1729770351,"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"BridgeBio (BBIO) Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of BBP-812, an...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BBP":"Virtus LifeSci Biotech Products ETF","BBIO":"BridgeBio Pharma, Inc.","BK4585":"ETF&股票定投概念","BK4505":"高瓴资本持仓","BK4588":"碎股","BK4139":"生物科技"},"translate_title":"BridgeBio分享BBP-812 Canaspire 1/2期试验的初步数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":1,"BBP":1},"content_text":"BridgeBio (BBIO) Pharma presented positive preliminary data from eleven participants dosed in the CANaspire Phase 1/2 clinical trial of BBP-812, an...","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477682302"}